AML, Childhood
Conditions
Brief summary
Pediatric patients (\<21 years at study entry) with relapsed or refractory acute myeloid leukemia (AML) will be treated with CD33\*CD3 a bispecific antibody to investigate the safety and tolerability of the drug.
Detailed description
This is an open label, first in human dose escalation trial in pediatric patients with relapsed or refractory acute myeloid leukemia to assess the safety and tolerability of increasing doses of CD33xCD3 BsAb administered subcutaneously. A modified Bayesian Optimal Interval Design (mBOIN) design will be applied. The trial will start with accelerated titration using single patient cohorts until one grade ≥2 AE not clearly associated to underlying disease, thereafter the trial will continue with mBOIN titration.
Interventions
DRUGCD33*CD3 BsAb
CD33xCD3 is a bispecific monoclonal antibody, which specifically targets CD33 on the AML blasts and CD3 on the T cells
Sponsors
Children's Oncology Group
Y-mAbs Therapeutics
Study design
Allocation
NA
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT
Masking
NONE
Intervention model description
open-label, single-arm, dose-escalation consisting of up to 12 cycles
Eligibility
Sex/Gender
ALL
Age
2 Years to 21 Years
Healthy volunteers
No
Inclusion criteria
* Signed informed consent from legal guardian(s), patient and/or child obtained in accordance with local regulations. Pediatric patients must provide assent as required by local regulations * Age ≥2 years, and ≤21 years, and a minimum body weight of ≥11 kg * Histologically confirmed relapsed or refractory AML (except acute promyelocytic leukemia) with no therapeutic options that may provide clinical benefit. Disease burden ≥5.0% in the bone marrow meets definition for enrollment. * Karnofsky performance status ≥50 for ≥16 years / Lansky performance status ≥50 for \<16 years * White blood cells (WBC) ≤25 x 109/L (may receive hydroxyurea to bring WBC count down prior to first dose of CD33xCD3 BsAb and during Cycle 1 or low dose cytarabine up to 48 h prior to first dose of CD33xCD3 BsAb) * Central Nervous System (CNS) disease as per Children's Oncology Group * Patients must have the status of CNS1 and no clinical signs or neurologic symptoms suggestive of CNS leukemia, such as cranial palsy * Patients with CNS3 or CNS2 status may receive antecedent intrathecal chemotherapy to achieve CNS1 status prior to trial entry * Patients with a history of CNS chloromatous disease are required to have no radiographic evidence of disease prior to enrollment * Has acceptable liver and kidney laboratory values * Patient must have recovered from acute toxic effects of prior anti-cancer therapies prior to first dose of CD33xCD3 BsAb
Exclusion criteria
* History of uncontrolled seizure. If on anti-convulsant and/or seizures are well controlled as per treating physician enrollment is acceptable * Acute promyelocytic leukemia with PML-RARA genetic abnormality according to WHO classification or t(15;17) * Isolated extramedullary AML * Clinically significant graft-versus-host disease (GvHD) secondary to prior allogeneic transplantation. No immunosuppressive therapy for ≥14 days prior to first dose, except for topical corticosteroids for minor rash (\<5% of BSA) or adrenal replacement therapy * Patient known to have one of the following genetic syndromes: Bloom syndrome, ataxia-telangiectasia, Fanconi anemia, Nijmegen breakage syndrome, Kostmann syndrome, Shwachman Diamond syndrome or any known bone marrow failure syndrome where increased risk for toxicity may be expected as judged by the Investigator * Treatment with another investigational agent under the following conditions: * Within two weeks (four weeks for biologics) before first administration of CD33xCD3 BsAb; or * Patient has persistent toxicities from prior anti-leukemic therapies which are determined to be relevant by the Investigator
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Occurrence of dose limiting toxicities (DLTs) | 28 days | Occurrence of DLTs during a DLT period . |
| Occurrence of Adverse Events | 52 weeks | Occurrence of Adverse Events during the trial |
Countries
United States
Outcome results
None listed